Equity Overview
Price & Market Data
Price: $10.50
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $393,125,248
Volume: 0
Performance Metrics
1 Week: 21.95%
1 Month: -12.43%
3 Months: -15.80%
6 Months: -65.56%
1 Year: -52.84%
YTD: -45.85%
Company Details
Employees: 28
Sector: Commercial services
Industry: Miscellaneous commercial services
Country:
Details
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.